Insulet Corp.
This article was originally published in Start Up
Executive Summary
Infusion pumps have been on the market for almost 20 years, but their cost and complexity have restricted their use to only 10% of insulin-dependent diabetics. Insulet Corp. hopes to penetrate further into the diabetes market with a credit-card sized disposable insulin pump that attaches to the body with an adhesive, and is controlled by a wireless remote unit.
You may also be interested in...
Device IPO Class of 2007 Making News, Some Returns
The merger of Accuray and TomoTherapy would combine two of the 11 medical device companies that went public in 2007, a class of companies that has produced mixed results.
The Wireless Age in Diabetes: Insulet Raises $50 Million
Insulet, developer of a fundamentally new insulin delivery system, just raised $50 million in its fifth venture round. This brings the total it's raised to date to more than $120 million, which sounds like a tremendous sum for a small device company founded just six years ago, but relative to the size of the opportunity it's really not. There are one million diabetic patients who need to inject insulin several times a day to manage their diabetes. For these patients, Insulet has brought insulin pumps into the age of iPods.
Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.